RxDoctor Payments Data

Kristen Caperna, PA

Physician Assistant · Bel Air, MDNPI 1033174438

Payments from drug & device makers

$4,218in general payments, 2019–2025

Across 156 payments — averaging $27.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$630
  • E.r. Squibb & Sons, L.L.C.$480
  • Scpharmaceuticals Inc.$311
  • Novo Nordisk$308
  • Novartis$304
  • Merck$283
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,12698%
  • Education$922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,218 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$93,279
Medicare patients
525
Services billed
1,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$159,424
XareltoRivaroxaban93$116,125
EntrestoSacubitril/Valsartan33$35,457
Repatha SureclickEvolocumab20$22,184
VascepaIcosapent Ethyl15$13,967
Ranolazine ErRanolazine53$6,769
Metoprolol Succinate298$6,003
Ezetimibe82$3,683
Atorvastatin Calcium234$3,324
Rosuvastatin Calcium104$2,930
Olmesartan Medoxomil73$2,269
Metoprolol Tartrate191$2,150
Hydralazine Hcl76$1,673
Carvedilol71$1,383
Flecainide Acetate28$1,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$181$159,424127 claims
Johnson & JohnsonXarelto$169$116,12593 claims
NovartisEntresto$304$35,45733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →